The effects of prolonged treatment with zidovudine, lamivudine, and abacavir on a T-lymphoblastoid cell line

AIDS Research and Human Retroviruses

Volumn 22, Issue 10, 2006, Pages 960-967

  Turriziani, Ombretta ^a,d   Pagnotti, Paolo ^a   Pierangeli, Alessandra ^a   Focher, Federico ^b   Baranello, Cinzia ^a   Bellomi, Francesca ^a   Falasca, Francesca ^a   Morgan, Jessica ^c   Schuetz, John D ^c   Antonelli, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CNR   (Italy)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CELL PROTEIN; DEOXYCYTIDINE KINASE; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN 4; PHOSPHATE; THYMIDINE KINASE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LONG TERM CARE; LYMPHOBLASTOID CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DEOXYCYTIDINE KINASE; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, NEOPLASM; HUMANS; LAMIVUDINE; LEUKEMIA, LYMPHOCYTIC; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PHENOTYPE; T-LYMPHOCYTES; THYMIDINE KINASE; ZIDOVUDINE;

EID: 33846257308     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.960     Document Type: Article

References (32)

1. Groschel B, Cinatl J, and Cinatl J Jr: Viral and cellular factors for resistance against antiretroviral agents. Intervirology 1997;14:400-407.
2. Fridland A, Connelly MC, and Robbins BL: Cellular factors for resistance against antiretroviral agents. Antiviral Ther 2000; 5:181-185.
3. Turriziani O and Antonelli G: Host factors and efficacy of antiretroviral treatment. New Microbiol 2004;27:63-70.
4. Wu S, Liu X, Solorzano MM, Kwock R, and Avramis VI: Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5′ end of human TK gene. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:1-9.
5. Antonelli G, Turriziani O, Verri A, Narciso P, Ferri F, D'Offizi G, and Dianzani F: Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase. AIDS Res Hum Retroviruses 1996;12:223-228.
6. Groschel B, Kaufmann A, Hover G, Cinatl J, Doerr HW, Noordhuis P, Loves WJ, Peters GJ, and Cinatl J Jr: 3′-Azido-2′,3′- dideoxythymidine induced deficiency of thymidine kinase 1, 2 and deoxycytidine kinase in H9 T-lymphoid cells. Biochem Pharmacol 2002;64:239-246.
7. Turriziani O, Scagnolari C, Bambacioni F, Bellomi F, Focher F, Gentile M, and Antonelli G: Selection of a T cell line resistant to d4T and AZT by prolonged treatment with d4T. Antiviral Ther 2002;7:105-111.
8. Turriziani O, Schuetz JD, Focher F, Scagnolari C, Sampath J, Adachi M, Bambacioni F, Riva E, and Antonelli G: Impaired 2′-3′-dideoxy- 3′-thiacytidine accumulation in CEM lymphoblastoid cells as a mechanism of acquired resistance independent of MRP4. Biochem J 2002;368:325-332.
9. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, and Fridland A: MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999;5:1048-1051.
10. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clercq E, Balzarini J, and Borst P: Mutidrug-resistance protein 5 is a multispecific anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 2000;97:7476-7481.
11. Denizot F and Lang R: Rapid colorimetric assay for cell growth and survival. J Immunol Methods 1986;89:271-277.
12. Ankel H, Turriziani O, and Antonelli G: Prostaglandin A inhibits replication of human immunodeficiency virus during acute infection. J Gen Virol 1991;72:2797-2800.
13. Hu JM and Hsiung GD: Evaluation of new antiviral agents: In vitro perspectives. Antiviral Res 1989;12:217-232.
14. Turriziani O, Butera O, Gianotti N, Parisi SG, Mazzi R, Girardi E, Iaiani G, Antonelli L, Lazzarin A, and Antonelli G: Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients. AIDS 2005;19:473-479.
15. Turriziani O, Antonelli G, Focher F, Bambacioni F, and Dianzani F: Further study on the mechanism underlying the cellular resistance to AZT. Biochem Biophys Res Commun 1996;228:797-801.
16. Ginzinger DG: Gene amplification using real-time quantitative PCR: An emerging technology hits the mainstream. Exp Hematol 2002;30:503-512.
17. Robbins BL, Rodman J, McDonald C, Srinivas RV, Flynn PM, and Fridland A: Enzymatic assay for the measurement of zidovudine triphosphate in peripheral blood mononuclear cells. Antimicrob Agents Chemother 1994;38:115-121.
18. Kewn S, Hoggard PG, Sales SD, Jones K, Maher B, Khoo SH, and Back DJ: Development of enzymatic assay for the quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected person. Antimicrob Agents Chemother 2002;46: 135-143.
19. Verri A, Focher F, Priori G, Gosselin G, Imbach JL, Capobianco M, Garbesi A, and Spadari S: Lack of enantiospecificity of human 2′-deoxycytidine kinase: Relevance for the activation of beta-L-deoxycytidine analogs as antineoplastic and antiviral agents. Mol Pharmacol 1997;51:132-138.
20. Spadari S, Maga G, Verri A, and Focher F: Molecular basis for the antiviral and anticancer activities of unnatural L-β-nucleosides. Exp Opin Invest Drugs 1998;7:1285-1300.
21. Wang X, Nitanda T, Shi M, Okamoto M, Furukawa T, Sugimoto Y, Akiyama S, and Baba M: Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. Biochem Pharmacol 2004;68(7):1363-1370.
22. Borst P, Balzarini J, Ono N, Reid G, de Vries H, Wielinga P, Wijnholds J, and Zelcer N: The potential impact of drug transporters on nucleoside-analog- based antiviral chemotherapy. Antiviral Res 2004;62:1-7.
23. Wang X and Baba M: The role of breast cancer resistance protein (BCRP/ ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Antiviral Chem Chemother 2005;16(4): 213-216.
24. Turriziani O, Gianotti N, Bambacioni F, Manconi PE, Lazzarin A, and Antonelli G: Lack of reduced thymidine kinase activity in stavudine treated HIV-infected patients. AIDS Res Hum Retroviruses 2004;20:701-703.
25. Han T, Fernandez M, Sarkar M, and Agarwal RP: Arabinosylcytosine downregulates thymidine kinase and induces cross-resistance to zidovudine in T-lymphoid cells. Biochem Biophys Res Commun 2003;307:564-568.
26. Han T, Fernandez M, Sarkar M, and Agarwal RP: 2′,3′- Dideoxycytidine represses thymidine kinases 1 and 2 expression in T-lymphoid cells. Life Sci 2004;74(7):835-842.
27. Sarkar M, Han T, Damaraju V, Carpenter P, Cass CE, and Agarwal RP: Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells. Biochem Pharmacol 2005;70(3):426-432.
28. Ito M and Conrad SE: Independent regulation of thymidine kinase mRNA and enzyme levels in serum-stimulated cells. J Biol Chem 1990;265:6954-6960.
29. Agarwal RP, Han T, and Fernandez M: Collateral resistance of dideoxycytidine-resistant cell line to 5-fluoro-2′deoxyuridine. Biochem Biophys Res Commun 1999;262:657-660.
30. Agarwal RP, Han T, and Fernandez M: Reduced cellular transport and activation of fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance. Biochem Pharmacol 2001;61:39-47.
31. Garvey EP and Krenitsky TA: A novel human phosphotransferase highly specific for adenosine. Arch Biochem Biophys 1992;296: 161-169.
32. Faletto MB, Miller WH, Garvey EP, St. Clair MH, Daluge SM, and Good SS: Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother 1997;41:1099-1107.